Evidence mapPaperPMID 42420701Full record

ReviewAdvances in experimental medicine and biology2026

Endothelial Surface Glycocalyx in Vascular Functions and Diseases.

Ye Zeng, Bingmei M Fu, John M Tarbell

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ye ZengInstitute of Biomedical Engineering, West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University, Chengdu, China. ye@scu.edu.cn.
Bingmei M FuDepartment of Biomedical Engineering, The City College of the City University of New York, New York, NY, USA.
John M TarbellDepartment of Biomedical Engineering, The City College of the City University of New York, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endothelial cells (ECs), which form the inner lining of the vasculature, are perpetually exposed to mechanical stimuli from blood flow. Their capacity to sense and respond to these forces is essential for vascular homeostasis. A diverse array of mechanosensors operates on the EC surface, within the plasma membrane, and throughout the cytoskeleton. Among these, the endothelial surface glycocalyx (ESG)-uniquely positioned at the blood-endothelium interface and intimately linked to classical mechanosensory complexes-has emerged as a pivotal yet underappreciated regulator. Once viewed merely as a passive barrier, the ESG is now acknowledged as a primary mechanosensor that converts hemodynamic forces into biochemical signals critical for vascular health. This updated chapter from the first edition offers a comprehensive review of the ESG. We begin with its molecular composition, ultrastructural organization, and variable thickness, as elucidated by advanced imaging techniques such as immunolabeling, electron microscopy, and super-resolution microscopy. Next, we examine the ESG's biomechanical properties and its central role in endothelial mechanotransduction and barrier regulation. We then explore its dynamic remodeling in response to physiological and pathological stimuli, with a focus on degradation in major vascular diseases. ESG shedding is not only a hallmark but also a causal driver of pathophysiology in conditions including atherosclerosis, sepsis, diabetes, cancer metastasis, and COVID-19-associated endotheliopathy. Finally, we spotlight emerging diagnostic tools for evaluating ESG integrity and review promising therapeutic strategies to preserve or restore its structure and function.

Indexed as

Endothelial CellsEndothelium, VascularGlycocalyxMechanotransduction, CellularVascular DiseasesAnimalsHumansAtherosclerosisCancer metastasisDiabetesEndothelial surface glycocalyx (ESG)Glycocalyx (GCX)GlycosaminoglycansMechanotransductionProteoglycansSepsisTherapeutic targeting

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.